Skip to main content

Articles

Clinical Assessment of Abuse-Deterrent Formulations
Read More
The Tip of the Iceberg
Read More
In Vitro and Clinical Assessments of Abuse-Deterrent Formulations in the Management of Chronic Pain
Read More
Conference Highlights ASH
Improving the Standard of Care
Read More
Perspectives
PEACE Time
Read More
Letters to the Editor
Correspondence: Cost of Treatment for Relapsed/Refractory Multiple Myeloma
Read More
Original Research, Practice Management
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Stakeholder Perspective
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Read More
Original Research
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice
Read More
Perspectives
Employers Engaged in Benefit Design Innovation: Long-Term Trends in a 2015 National Survey
Read More
Original Research
Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis
Stakeholder Perspective
You Cannot Manage What You Cannot Measure
Read More
Page 122 of 245
Results 1211 - 1220 of 2441